Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

NVO trades at roughly 10 times earnings, well below its five-year average P/E of 24x, after a 70% slide from its 2024 high. The discount arrives alongside a $2.2 billion stock buyback, a signal that management sees the shares as undervalued.

The damage traces to GLP-1 weight-loss drugs, where NVO has ceded market share to LLY. The source attributes the loss to supply issues and efficacy concerns. NVO's response is a pivot to a volume-driven model, anchored by a pill version of its drug. A 4.6% dividend yield adds an income cushion for holders waiting on a recovery.

Interpretation: a 10x multiple against a 24x average prices in a lot of bad news. The market appears to be treating the share loss to LLY as structural rather than temporary. If the pill strategy restores growth, the gap between current and historical multiples leaves room for rerating. If it doesn't, the discount could persist, and the buyback and dividend become the main supports.

The bull case rests on valuation and capital return, not on any demonstrated reversal in market share. That distinction matters for sizing.